360b-shutterstock-com-allergan-
360b / Shutterstock.com
4 October 2016Americas

Allergan and MedImmune enter $1.5bn licensing deal

Allergan and MedImmune have entered into a $1.52 billion licensing agreement under which Allergan has gained the global rights to develop MEDI2070, which treats inflammatory disorders.

MedImmune is AstraZeneca’s global biologics research and development (R&D) company.

MEDI2070 is an antibody which is still in development for the treatment of patients with moderate to severe Crohn’s disease.

Allergan will make an upfront payment to AstraZeneca of $250 million for the exclusive, worldwide licence to develop and commercialise MEDI2070.

David Nicholson, chief researcher and development officer at Allergan, said in a statement: “MEDI2070 represents an exciting addition to our open science pipeline, adding an important new programme currently being studied in Crohn’s disease, with potential across a number of inflammatory and autoimmune disorders.

He added: “The MEDI2070 programme also reinforces Allergan’s commitment to bringing forward important innovations in the treatment of inflammation and autoimmune disorders where significant unmet need exists across many of our therapeutic areas.”

Bahija Jallal, executive vice president of Medimmune, said: “This agreement demonstrates our sharp focus on three main therapy areas while creating value from the increased R&D productivity and innovative science in our pipeline through collaborations.”

She added: “Allergan has significant experience in gastrointestinal and inflammatory diseases and is the right partner to progress the development and commercialisation of MEDI2070.”

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
11 September 2017   Allergan has transferred its patent rights for a dry eye treatment to a Native American tribe, in a bid to obtain immunity against an inter partes review (IPR).

More on this story

Americas
11 September 2017   Allergan has transferred its patent rights for a dry eye treatment to a Native American tribe, in a bid to obtain immunity against an inter partes review (IPR).

More on this story

Americas
11 September 2017   Allergan has transferred its patent rights for a dry eye treatment to a Native American tribe, in a bid to obtain immunity against an inter partes review (IPR).